QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women's Health Genetic Screening
October 19 2017 - 4:36PM
PR Newswire (US)
ORLANDO, GERMANTOWN, Maryland, and HILDEN, Germany, October 19,
2017 /PRNewswire/ --
QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) today
announced the results of a study evaluating the accuracy of the
QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic
screening and genetic counseling company. In an evaluation,
Counsyl - an early QCI adopter - found that it reduced the time
required to search for literature references to interpret and score
variants by 75 percent while maintaining accuracy. As a result,
Counsyl has implemented QCI as an integral part of its literature
search process to increase productivity and scalability. Results of
the evaluation are presented today in a poster at the American
Society of Human Genetics (ASHG).
Click here for the full press release
https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-19-Counsyl-ASHG?sc_lang=en
Contacts:
Investor Relations
John Gilardi
E-Mail: ir@QIAGEN.com
+49-2103-29-11711
Public Relations
Dr. Thomas Theuringer
E-Mail: pr@QIAGEN.com
+49-2103-29-11826
SOURCE QIAGEN
Copyright 2017 PR Newswire
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024